Actively Recruiting
Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo
Led by Jiangsu vcare pharmaceutical technology co., LTD · Updated on 2026-01-02
120
Participants Needed
1
Research Sites
95 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This clinical trial is a multicenter, randomized, double-blind, controlled phase II clinical study
CONDITIONS
Official Title
Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo
Who Can Participate
Eligibility Criteria
You may qualify if you...
- The subject understands and voluntarily signs the informed consent form (ICF) and is willing and able to comply with the study protocol.
- The subject is between 18 and 70 years of age (including borderline values), regardless of gender.
You will not qualify if you...
- Pregnant or lactating women, or subjects with pregnancy or lactation plans during the study period.
- All hair in the vitiligo area on the face is white.
- Those who are known or suspected to be allergic to the main ingredients and excipients of VC005 or similar drugs.
- Subjects who have previously received depigmentation treatment.
- Subjects who have received experimental drug administration or participated in device clinical trials within the first month or 5 half lives (whichever is longer) prior to randomization.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Peking University People's Hospital
Beijing, Beijng, China
Actively Recruiting
Research Team
X
xiaojuan lai
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here